Amarin (NASDAQ:AMRN) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of Amarin (NASDAQ:AMRN) from a hold rating to a strong sell rating in a research report released on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($2.93) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($2.71) EPS, Q2 2026 earnings at ($2.55) EPS, Q3 2026 earnings at ($4.22) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($17.05) EPS, Q1 2027 earnings at ($2.77) EPS, Q2 2027 earnings at ($2.77) EPS, Q3 2027 earnings at ($3.33) EPS, Q4 2027 earnings at ($6.46) EPS and FY2027 earnings at ($15.33) EPS.

Several other research analysts have also commented on the company. Wall Street Zen lowered Amarin from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a research report on Wednesday, January 21st. Three analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Sell” and an average price target of $12.00.

Amarin Price Performance

Shares of Amarin stock opened at $15.42 on Tuesday. The stock’s 50 day simple moving average is $14.89 and its 200-day simple moving average is $15.80. The stock has a market cap of $320.58 million, a P/E ratio of -6.19 and a beta of 0.72. Amarin has a 1-year low of $7.08 and a 1-year high of $20.90.

Institutional Trading of Amarin

Several institutional investors and hedge funds have recently bought and sold shares of AMRN. Waterfront Wealth Inc. boosted its stake in Amarin by 82.8% during the fourth quarter. Waterfront Wealth Inc. now owns 142,540 shares of the biopharmaceutical company’s stock worth $1,990,000 after buying an additional 64,580 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Amarin by 534.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,754 shares of the biopharmaceutical company’s stock valued at $356,000 after acquiring an additional 18,324 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Amarin by 1,816.7% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 5,450 shares during the last quarter. Millennium Management LLC boosted its position in shares of Amarin by 192.6% during the 3rd quarter. Millennium Management LLC now owns 132,391 shares of the biopharmaceutical company’s stock worth $2,169,000 after purchasing an additional 87,147 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in Amarin by 13.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 2,008 shares during the last quarter. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.